Mixed analyst views on this largecap pharma stock despite 27% jump in Q1 profit; slips nearly 3%
Divi’s Laboratories Share Price Target: Even after reporting a healthy financial performance in Q1 FY26, Divi’s Laboratories is facing cautious ratings from global brokerage analysts. The Hyderabad-based largecap drug maker reported a consolidated net profit of Rs 545 crore during the quarter, marking a 27 per cent year-on-year (YoY) jump. Revenue from operations also rose 13.8…